IP Library Granted Patent US 10,808,232
Granted Patent B2
US 10,808,232 · App. 15/438,638 · Granted Oct 20, 2020

Dynamically-adaptive live therapeutic agents and methods of use thereof

Inventors: Mimi-Cho Yung (Milpitas, CA); Matthew A. Coleman (Oakland, CA); Patrik D'haeseleer (Alameda, CA); Howard Harris (Los Angeles, CA); Yongqin Jiao (Pleasanton, CA); Kenneth W. Overton (San Jose, CA); Dan Mcfarland Park (Dublin, CA); Brent W. Segelke (San Ramon, CA); Sergio E. Wong (Tracy, CA)
Assignee: Lawrence Livermore National Security, LLC
C12N9/22C07K14/00C07K14/245C07K14/315C07K14/33C12N15/11C12Q1/04A61K35/74C12N2310/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,808,232
App. No.
15/438,638
Granted
Oct 20, 2020
Kind
B2
Abstract

This disclosure provides microbes engineered to detect virulent and spore states of pathogens and release an appropriate therapeutic response accordingly and compositions and methods of use of the same.

Claims (12)

1. A genetically engineered viable Lactobacillus or Lactococcus probiotic bacterium comprising a dual pathogen state detection system, the dual pathogen detection system comprising:

a first sensor for detection of a large clostridial toxin (LCT) secreted by a virulent form of Clostridium difficile (C. diff), wherein the first sensor is operatively connected to a virulent secretion system, wherein the virulent secretion system produces one or more agents in an encapsulated shell and

a second sensor for detection of a cell surface protein on a spore form of C. diff, wherein the second sensor is operatively connected to a spore secretion system, wherein the spore secretion system produces an encapsulated agent.

2. The genetically engineered probiotic bacterium of claim 1 , wherein the first sensor is an antibody or a functionally active epitope binding fragment thereof that immunospecifically binds to the large clostridial toxin and the second sensor is an antibody or an epitope binding fragment thereof that immunospecifically binds to the cell surface protein.

3. The genetically engineered probiotic bacterium of claim 2 , wherein the antibody is a monoclonal antibody or a polyclonal antibody.

4. The genetically engineered probiotic bacterium of claim 1 , wherein the large clostridial toxin is C. difficile toxin A (TcdA) or C. difficile toxin B (TcdB).

5. The genetically engineered probiotic bacterium of claim 1 , wherein the cell surface protein is a spore coat protein of C. difficile.

6. The genetically engineered probiotic bacterium of claim 5 , wherein the spore coat protein is the BclA glycoprotein or the cysteine-rich protein CdeC.

7. The genetically engineered probiotic bacterium of claim 1 , wherein the one or more agents in the encapsulated shell is an endolysin.

8. The genetically engineered probiotic bacterium of claim 1 , wherein the one or more agents in the encapsulated shell is a bacteriocin selected from the group consisting of colicin, diffocin, pyocin, and rhuricin 17.

9. The genetically engineered probiotic bacterium of claim 1 , wherein the encapsulated agent induces germination of the spore.

10. The genetically engineered probiotic bacterium of claim 1 , wherein the encapsulated agent is a bile salt or a protease.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jun 7, 2017
From: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
To: U.S. DEPARTMENT OF ENERGY
Reel/Frame 042637/0249 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2017
From: YUNG, MIMI-CHO; COLEMAN, MATTHEW A.; D'HAESELEER, PATRIK; HARRIS, HOWARD; JIAO, YONGQIN; OVERTON, KENNETH W.; PARK, DAN MCFARLAND; SEGELKE, BRENT W.; WONG, SERGIO E.
To: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
Reel/Frame 041327/0699 →
Continuity (1)
Related Publication 20180236012A1 · Aug 23, 2018